Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18206 participants.

Also called NCT01107886

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 18,206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01107886
Other papers using this trial's data
  • Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial JAMA cardiology, 2018-02-01 DOI, PubMed 29214305, PMC6594440 Not in the PMC Open Access subset.
  • Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c The American journal of medicine, 2016-03 DOI, PubMed 26524706
  • Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial Diabetes care, 2017-01 DOI, PubMed 27797925
  • Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial Diabetes care, 2015-06 DOI, PubMed 25758769
  • Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial Circulation, 2014-10-28 DOI, PubMed 25189213 PubMed links an erratum for this paper. Erratum: PMID 26459088
  • Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial Diabetes care, 2015-11 DOI, PubMed 26358285
  • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial Diabetes care, 2015-04 DOI, PubMed 25552421
  • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus The New England journal of medicine, 2013-10-03 DOI, PubMed 23992601

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong SAR China, Hungary, India, Israel, Italy, Mexico, Netherlands, Peru, Poland, Puerto Rico, Russia, South Africa, Spain, Sweden, Taiwan, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01107886. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
Acronym
SAVOR- TIMI 53
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01107886
Content hash
c40846c4fd70940b6d670371539ed23d99794cdc68beda62f1a168f52dd40ad9